A Randomized, Open-Label, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy

Biotechnology Computer Science Energy Engineering Environmental Sciences Information Science Life Sciences Mathematics Medical Sciences

Military Sciences Natural Sciences Physical Sciences Plant Sciences Science Space Sciences Technology Transportation